Literature DB >> 32245829

Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization: Implications for Viral Infection-Induced Pain.

Paulino Barragán-Iglesias1,2, Úrzula Franco-Enzástiga3, Vivekanand Jeevakumar1, Stephanie Shiers1, Andi Wangzhou1, Vinicio Granados-Soto3, Zachary T Campbell4, Gregory Dussor1, Theodore J Price5.   

Abstract

One of the first signs of viral infection is body-wide aches and pain. Although this type of pain usually subsides, at the extreme, viral infections can induce painful neuropathies that can last for decades. Neither of these types of pain sensitization is well understood. A key part of the response to viral infection is production of interferons (IFNs), which then activate their specific receptors (IFNRs) resulting in downstream activation of cellular signaling and a variety of physiological responses. We sought to understand how type I IFNs (IFN-α and IFN-β) might act directly on nociceptors in the dorsal root ganglion (DRG) to cause pain sensitization. We demonstrate that type I IFNRs are expressed in small/medium DRG neurons and that their activation produces neuronal hyper-excitability and mechanical pain in mice. Type I IFNs stimulate JAK/STAT signaling in DRG neurons but this does not apparently result in PKR-eIF2α activation that normally induces an anti-viral response by limiting mRNA translation. Rather, type I IFNs stimulate MNK-mediated eIF4E phosphorylation in DRG neurons to promote pain hypersensitivity. Endogenous release of type I IFNs with the double-stranded RNA mimetic poly(I:C) likewise produces pain hypersensitivity that is blunted in mice lacking MNK-eIF4E signaling. Our findings reveal mechanisms through which type I IFNs cause nociceptor sensitization with implications for understanding how viral infections promote pain and can lead to neuropathies.SIGNIFICANCE STATEMENT It is increasingly understood that pathogens interact with nociceptors to alert organisms to infection as well as to mount early host defenses. Although specific mechanisms have been discovered for diverse bacterial and fungal pathogens, mechanisms engaged by viruses have remained elusive. Here we show that type I interferons, one of the first mediators produced by viral infection, act directly on nociceptors to produce pain sensitization. Type I interferons act via a specific signaling pathway (MNK-eIF4E signaling), which is known to produce nociceptor sensitization in inflammatory and neuropathic pain conditions. Our work reveals a mechanism through which viral infections cause heightened pain sensitivity.
Copyright © 2020 the authors.

Entities:  

Keywords:  MNK; dorsal root ganglion; eIF4E; nociceptor; type I interferon

Year:  2020        PMID: 32245829      PMCID: PMC7189756          DOI: 10.1523/JNEUROSCI.3055-19.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  64 in total

1.  Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection.

Authors:  Liang Cheng; Haisheng Yu; Guangming Li; Feng Li; Jianping Ma; Jingyun Li; Liqun Chi; Liguo Zhang; Lishan Su
Journal:  JCI Insight       Date:  2017-06-15

Review 2.  Tinkering with translation: protein synthesis in virus-infected cells.

Authors:  Derek Walsh; Michael B Mathews; Ian Mohr
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

Review 3.  Interferon signatures in immune disorders and disease.

Authors:  Samuel Forster
Journal:  Immunol Cell Biol       Date:  2012-04-10       Impact factor: 5.126

4.  eIF2α phosphorylation controls thermal nociception.

Authors:  Arkady Khoutorsky; Robert E Sorge; Masha Prager-Khoutorsky; Sophie Anne Pawlowski; Geraldine Longo; Seyed Mehdi Jafarnejad; Soroush Tahmasebi; Loren J Martin; Mark H Pitcher; Christos G Gkogkas; Reza Sharif-Naeini; Alfredo Ribeiro-da-Silva; Charles W Bourque; Fernando Cervero; Jeffrey S Mogil; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

5.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 6.  The multiple faces of proteinkinase R in antiviral defense.

Authors:  Muhammad Munir; Mikael Berg
Journal:  Virulence       Date:  2013-01-01       Impact factor: 5.882

7.  Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction.

Authors:  A C Larner; A Chaudhuri; J E Darnell
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

8.  IFNβ Treatment Inhibits Nerve Injury-induced Mechanical Allodynia and MAPK Signaling By Activating ISG15 in Mouse Spinal Cord.

Authors:  Su Liu; Stephen Karaganis; Ru-Fan Mo; Xiao-Xiao Li; Ruo-Xin Wen; Xue-Jun Song
Journal:  J Pain       Date:  2019-11-27       Impact factor: 5.820

Review 9.  Translational Control Mechanisms in Persistent Pain.

Authors:  Arkady Khoutorsky; Theodore J Price
Journal:  Trends Neurosci       Date:  2018-02       Impact factor: 13.837

Review 10.  Interferon target-gene expression and epigenomic signatures in health and disease.

Authors:  Franck J Barrat; Mary K Crow; Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2019-11-19       Impact factor: 25.606

View more
  16 in total

1.  Interactions between nociceptor sensory neurons and microbial pathogens in pain.

Authors:  Larissa Staurengo-Ferrari; Liwen Deng; Isaac M Chiu
Journal:  Pain       Date:  2022-11-01       Impact factor: 7.926

2.  PML-NB-dependent type I interferon memory results in a restricted form of HSV latency.

Authors:  Jon B Suzich; Sean R Cuddy; Hiam Baidas; Sara Dochnal; Eugene Ke; Austin R Schinlever; Aleksandra Babnis; Chris Boutell; Anna R Cliffe
Journal:  EMBO Rep       Date:  2021-07-01       Impact factor: 9.071

3.  STING controls nociception via type I interferon signalling in sensory neurons.

Authors:  Christopher R Donnelly; Changyu Jiang; Amanda S Andriessen; Kaiyuan Wang; Zilong Wang; Huiping Ding; Junli Zhao; Xin Luo; Michael S Lee; Yu L Lei; William Maixner; Mei-Chuan Ko; Ru-Rong Ji
Journal:  Nature       Date:  2021-01-13       Impact factor: 69.504

Review 4.  Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.

Authors:  Candice Mazewski; Ricardo E Perez; Eleanor N Fish; Leonidas C Platanias
Journal:  Front Immunol       Date:  2020-11-23       Impact factor: 7.561

Review 5.  Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain.

Authors:  Amelia J McFarland; Muhammad S Yousuf; Stephanie Shiers; Theodore J Price
Journal:  Pain Rep       Date:  2021-01-07

Review 6.  Innate Receptors Expression by Lung Nociceptors: Impact on COVID-19 and Aging.

Authors:  Carlos H Hiroki; Nicole Sarden; Mortaza F Hassanabad; Bryan G Yipp
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 7.  Interferons in Pain and Infections: Emerging Roles in Neuro-Immune and Neuro-Glial Interactions.

Authors:  Ping-Heng Tan; Jasmine Ji; Chun-Chang Yeh; Ru-Rong Ji
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

Review 8.  Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain.

Authors:  Muhammad Saad Yousuf; Stephanie I Shiers; James J Sahn; Theodore J Price
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 9.  Infection-Associated Mechanisms of Neuro-Inflammation and Neuro-Immune Crosstalk in Chronic Respiratory Diseases.

Authors:  Belinda Camp; Sabine Stegemann-Koniszewski; Jens Schreiber
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

10.  STING suppresses bone cancer pain via immune and neuronal modulation.

Authors:  Kaiyuan Wang; Christopher R Donnelly; Changyu Jiang; Yihan Liao; Xin Luo; Xueshu Tao; Sangsu Bang; Aidan McGinnis; Michael Lee; Matthew J Hilton; Ru-Rong Ji
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.